SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results
August 14, 2018 06:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics
July 31, 2018 06:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd.
July 20, 2018 06:00 ET | SteadyMed Therapeutics
SILVER SPRING, Md. and SAN RAMON, Calif., July 20, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ:STDY) announced today the termination of the...
SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results
May 15, 2018 08:00 ET | SteadyMed Therapeutics
SAN RAMON, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
United Therapeutics to Acquire SteadyMed Ltd.
April 30, 2018 06:00 ET | SteadyMed Therapeutics
SILVER SPRING, Md. and SAN RAMON, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ:STDY) announced today the signing of a...
SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
March 30, 2018 15:15 ET | SteadyMed Therapeutics
SAN RAMON, Calif., March 30, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission
December 08, 2017 06:55 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal Circuit
November 14, 2017 09:56 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 13, 2017 08:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Receives Notice of Allowance for its European Patent Relating to Enhanced Reduction of Infusion-Site Pain
October 12, 2017 08:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...